Tweet This

Premium Increase Review

Insurance providers are required to explain, to state and federal officials, any 'unreasonable' premium increases.

Biosimilars User Fee Act

Creates an abbreviated licensure pathway for biologic products that are demonstrated to be “biosimilar” to or “interchangeable” with an FDA-licensed biologic product. This pathway is…